This content is machine translated SARS-CoV-2 Nirmatrelvir against long-covid risk – new trial data are encouraging A large retrospective cohort study based on data from the U.S. Department of Veterans Affairs addressed the question of whether treatment with the antiviral drug nirmatrelvir within five days of…
